secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001193125-23-274506
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd Q3 net loss $0.36/sh; completes CANOPY Phase 3 enrollment, data expected late 2023/early Q1
--------------------------------------------------------------------------------

- Enrolled ~750 participants in CANOPY Phase 3 trial of VYD222 to prevent symptomatic COVID-19.
- Cash, equivalents and marketable securities $264.9M as of Sept 30, 2023; runway into Q4 2024.
- Net loss $39.4M ($0.36 per share) for Q3 2023, compared to $45.1M ($0.42) in Q3 2022.
- VYD222 shows in vitro neutralizing activity against Omicron variants including XBB.1.5.10/EG.5 with F456L mutation.
- Appointed William Duke as CFO on Sept 5, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312523274506/0001193125-23-274506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312523274506/d295277d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-274506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer